Biohope at American Transplant Congress ATC2026.
Proud to see our team on the ground at the American Transplant Congress (ATC) 2026 in Boston! Isabel and Joshua are there representing Biohope, engaging with the transplant community, sharing insights, and exploring new collaborations around precision medicine in immunology. ATC is a key meeting point for innovation in transplantation, and we are delighted to be part of the conversation driving better outcomes for patients. If you’re attending, feel free to connect with them! #ATC2026 #Transplantation #PrecisionMedicine #Immunology #Innovation #Biohope
Immunobiogram® launches in Mexico thanks to a partnership between Biohope and Grupo Vanquish
Biohope Scientific Solutions for Human Health and Grupo Vanquish announce the launch of Immunobiogram® in Mexico, a milestone that marks a new step in the international expansion of this innovative immunology diagnostic solution. From this month, Immunobiogram® is available in Mexico, offering healthcare professionals a tool that provides functional information on how each patient responds to immunosuppressive treatments. This approach enables progress towards more personalised medicine, supporting clinical decision-making with information tailored to each patient. The launch is the result of a strategic collaboration between Biohope, a Spanish company specialising in precision in vitro diagnostics, and Grupo Vanquish, a Mexican company with a solid track record in introducing innovative technologies into the country’s healthcare system. For Biohope, the arrival of Immunobiogram® in Mexico reinforces its mission to bring precision medicine into real-world clinical practice across various international markets. For Vanquish, it means expanding its offering with a differentiated solution, in line with its commitment to innovation and the continuous improvement of healthcare. Both companies share the vision that precision diagnostics is a key driver for improving clinical outcomes and contributing to more efficient healthcare systems. The launch of Immunobiogram® in Mexico is a firm step in that direction.
Biohope partners with Duraent Lifesciences to introduce Immunobiogram® in India
We are proud to partner with Duraent Lifesciences to introduce Immunobiogram® in India, scaling access through a partner-led model At Biohope, we built Immunobiogram®: a CE‑marked, patented pharmacodynamic IVD that maps a patient’s immune-cell response to immunosuppressants and delivers actionable drug‑sensitivity insights. Kidney transplant immunosuppression is still managed largely by trial-and-error, despite the cost of rejection, infection and toxicity. By enabling clinicians to better understand how each patient’s immune system reacts to treatment, Immunobiogram® supports more precise therapeutic decisions and contributes to improving outcomes in kidney transplantation. Every transplant journey deserves precision. Every patient deserves personalized care
National Kidney Foundation (NKF) Innovation Fund invests in Biohope
We are proud to share that the National Kidney Foundation (NKF) Innovation Fund has invested in Biohope to advance personalized medicine in kidney transplantation. This investment will support further clinical validation and progress toward U.S. regulatory approval of Immunobiogram®, our in vitro diagnostic technology designed to personalize immunosuppressive therapy for kidney transplant recipients—helping reduce complications and extend graft survival. Today, immunosuppression management is still largely based on trial and error, exposing patients to significant risks. Immunobiogram® analyzes how a patient’s immune cells respond to different immunosuppressive drugs, providing actionable insights to support more precise clinical decision-making. The platform is already commercially available in Spain and has been evaluated in more than 1,000 patients across multiple clinical studies. Having the support of the National Kidney Foundation, an organization with a deep understanding of the real needs of patients and clinicians, is a meaningful step forward in bringing personalized medicine into routine clinical practice and improving outcomes in kidney transplantation. We remain committed to a clear mission: putting each patient’s individual biology at the center of clinical decision-making. For more information, you can read the official press release published by the National Kidney Foundation on its website. The announcement has also been distributed via PR Newswire.
Biohope Welcomes Virginia González as New Chief Executive Officer
Biohope is glad to announce the appointment of Virginia González as its new Chief Executive Officer, marking an important milestone in the company’s evolution after more than ten years of growth and scientific consolidation. As CEO, Virginia González will lead Biohope into its next phase of development, with a strong focus on accelerating the company’s commercial development, expanding market presence, and strengthening strategic partnerships. Her leadership will build on Biohope’s solid scientific foundation while driving sustainable growth and transforming innovation into broader clinical and commercial impact. Following this transition, Isabel Portero, Founder and former Chief Executive Officer of Biohope, will continue with the company as Chief Scientific Officer (CSO). In this role, she will remain responsible for leading Biohope’s scientific and strategic vision, ensuring continuity and excellence in research, innovation, and clinical development. “We are delighted to welcome Virginia González as CEO of Biohope,” said Isabel. “Her leadership, vision, and strong business focus align perfectly with our current stage and long-term strategy. We are confident that this new chapter will further strengthen Biohope’s position as a leader in precision medicine.” This leadership evolution reflects Biohope’s maturity as an organization and reinforces its commitment to combining scientific excellence with commercial growth. The entire Biohope team warmly [...]
Biohope Announces Collaboration to Advance Immunobiogram for Renal Transplant
Madrid, Spain, November 3rd, 2025 – Biohope, a Spanish company specialized in personalized medicine solutions for transplant and autoimmune patients, has signed a know-how agreement with Mayo Clinic, a global leader in medical research and patient care, to advance the development and commercialization of the Immunobiogram, an in vitro diagnostic (IVD) device developed by Biohope and patented in the U.S. and other territories. The agreement grants Biohope access to Mayo Clinic’s specialized know-how, and seeks to enhance the clinical validation of the Immunobiogram in the US. This technology aims to optimize immunosuppression management by providing personalized diagnostic insights, potentially reducing rejection rates, infections, and improving graft survival and patient-reported outcomes (PRO). “We are thrilled to collaborate with Mayo Clinic, to utilize their expertise in transplant medicine,” said Isabel Portero, CEO of Biohope. “This agreement marks a significant step toward our goal of bringing Immunobiogram technology to market and offering transplant patients and clinicians a transformative tool for personalized immunosuppression management.” About Biohope Biohope is a biotechnology company dedicated to developing innovative diagnostic solutions for transplant patients. Its patented Immunobiogram technology provides personalized insights into immunosuppression sensitivity, aiming to enhance patient outcomes and quality of life. Note: Mayo Clinic has a financial interest in the [...]
Biohope Publishes New Pilot Study in Rheumatoid Arthritis, Opening the Path to a Novel Predictive Test
Biohope is proud to announce the publication of its latest scientific contribution in PLOS ONE: “Precision Medicine in Rheumatoid Arthritis: Evaluation of a New Approach to Predict Clinical Response to Methotrexate in Patients with Early Rheumatoid Arthritis”. This pilot clinical study explored whether simple in vitro blood tests could help predict which patients with early, methotrexate-naïve rheumatoid arthritis would respond to methotrexate, the gold-standard first-line therapy. The study followed 31 patients for six months and revealed that those who eventually achieved clinical remission showed distinct biological profiles before treatment. Specifically, the analized biomarkers demonstrated a high predictive capacity, suggesting that clinicians may be able to identify likely responders before initiating therapy. Although larger studies are required to confirm these findings, the general conclusion is clear: early prediction of methotrexate response through peripheral blood tests may soon become a reality. This opens the way for precision medicine approaches in rheumatoid arthritis, reducing delays in effective treatment and sparing patients from unnecessary exposure to ineffective therapies. At Biohope, we are transforming this knowledge into innovation. The encouraging results of this pilot study pave the way for the development of a new predictive diagnostic product that could guide therapeutic decisions in rheumatoid arthritis. We are pleased to [...]
Biohope presents the results of the BIOTRAIM study at the WTC’25 and they are selected among the most relevant abstracts in kidney transplantation
Biohope participated in the World Transplant Congress (WTC 2025) in San Francisco from 3 to 6 August 2025. We presented two oral communications on the results of the BIOTRAIM study. The WTC 2025 was the most important event of the year in the field of transplantation, as this edition integrated the ATC (American Transplant Association) congress, which was held separately in previous years. With the aim of addressing the issues that concern nephrologists around the world the most, Dr Ali reviewed the 1,550 abstracts submitted to the congress in the field of renal transplantation, making an initial selection of 50 and a final selection of 30. The abstract presented by Biohope, with the results of the BIOTRAIM study, was selected and its results were presented at the closing plenary session ('Reflection, Revelations and the Road Ahead'), in which the most relevant data from the congress are summarised. The WTC congress represents a strategic opportunity for Biohope to raise awareness of its technology and the results of its clinical research studies among the international transplant community. It is a space for interaction with thought leaders and companies from around the world, as well as a forum for scientific updates in this field. Biohope aims to [...]